Hodgie, one thing to consider mate.....I will suggest that the circa 5%
value from Goetz is purely for the partnership with GSK, I don't think
any valuation would be based on pre-clinical research....
The market certainly wouldn't, the news out in the next week or so
will give us a better indication of where 761 is headed.....
just my thoughts...
Immunotherapy Market value, page-40
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.8¢ |
Change
0.003(0.82%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 32.5¢ | 30.5¢ | $249.0K | 801.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 114265 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 76614 | 18 |
View Market Depth
| Last trade - 11.31am 25/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
